Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population
Preliminary boost study data also reported
Norovirus has been estimated to cost the United States $10.6 billion annually
https://finance.yahoo.com/news/vaxart-reports-positive-preliminary-data-123000225.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.